Dual delivery of carbon monoxide and doxorubicin using haemoglobin–albumin cluster: proof of concept for well-tolerated cancer therapy
- 7 May 2024
- journal article
- research article
- Published by Royal Society of Chemistry (RSC) in Journal of Materials Chemistry B
- Vol. 12 (23) , 5600-5608
Abstract
A serious concern of doxorubicin (DOX) therapy is that it causes severe adverse effects, particularly cardiotoxicity. Carbon monoxide (CO) possesses powerful cytoprotective effects against drug-induced organ injury and is expected to ameliorate DOX-induced cardiotoxicity. In this study, a dual carrier of DOX and CO (CO-HemoAct-DOX) was fabricated based on a haemoglobin–albumin cluster (HemoAct), which is a protein cluster with a haemoglobin core structure wrapped by serum albumin. CO-HemoAct-DOX was synthesised by binding CO to a haemoglobin core and covalently conjugating (6-maleimidocaproyl)hydrazone derivative of DOX to an albumin shell. The average DOX/cluster ratio was about 2.6. In the in vitro cytotoxicity assay against cancer cells, the anti-tumour activity of CO-HemoAct-DOX was 10-fold lower than that of DOX in a 2D-cultured model, whereas CO-HemoAct-DOX suppressed the growth of tumour spheroids to the same extent as DOX in the 3D-cultured model. In colon-26 tumour-bearing mice, CO-HemoAct-DOX achieved DOX delivery to the tumour site and alleviated tumour growth more effectively than DOX. Furthermore, CO-HemoAct attenuated DOX-induced cardiomyocyte atrophy in H9c2 cells and elevated the levels of cardiac biomarkers in mice exposed to DOX. These results suggest that the dual delivery of CO and DOX using HemoAct is a promising strategy as an anti-tumour agent to realise well-tolerated cancer therapy with minimal cardiotoxicity.Keywords
Funding Information
- Japan Science and Technology Agency (JPMJSP2123)
- Mochida Memorial Foundation for Medical and Pharmaceutical Research
This publication has 40 references indexed in Scilit:
- Trastuzumab potentiates doxorubicin-induced cardiotoxicity via activating the NLRP3 inflammasome in vivo and in vitroBiochemical Pharmacology, 2023
- Carbon monoxide (CO)/heme oxygenase (HO)-1 in gastrointestinal tumors pathophysiology and pharmacology - possible anti- and pro-cancer activitiesBiochemical Pharmacology, 2022
- Nanoformulation of a carbon monoxide releasing molecule protects against cyclosporin A-induced nephrotoxicity and renal fibrosis via the suppression of the NLRP3 inflammasome mediated TGF-β/Smad pathwayActa Biomaterialia, 2022
- Hemoglobin–albumin clusters as an artificial O2 carrier: Physicochemical properties and resuscitation from hemorrhagic shock in ratsJournal of Biomedical Materials Research Part B: Applied Biomaterials, 2022
- Harnessing carbon monoxide-releasing platforms for cancer therapyBiomaterials, 2020
- Investigation of anti-tumor effect of doxorubicin-loaded human serum albumin nanoparticles prepared by a desolvation techniqueCancer Chemotherapy and Pharmacology, 2019
- Roles of Albumin‐Binding Proteins in Cancer Progression and Biomimetic Targeted Drug DeliveryChemBioChem, 2018
- Multicellular Tumor Spheroids (MCTS) as a 3D In Vitro Evaluation Tool of NanoparticlesSmall, 2018
- Recent advances of transformable nanoparticles for theranosticsChinese Chemical Letters, 2017
- The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivoAdvanced Drug Delivery Reviews, 2013